⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 6, 2025Open Access

Table 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors

Christopher H. Lieu Heinz‐Josef Lenz Al B. Benson Xue Meng Uk-Il Kim Song Hyun Kim Kyungjin Kim Moo Je Sung

View Full Paper

Ask AI

Bookmark

Share

Key Points

Basroparib demonstrated safety and potential efficacy in patients with advanced-stage solid tumors, indicating further investigation is warranted.
This phase I trial included 25 patients, revealing promising activity against advanced cancers treated with basroparib.
The dose-escalation study design aims to identify the safest and most effective dosage for future research on tankyrase inhibitors.
Outcomes highlight the need for follow-up studies to validate the role of tankyrase inhibitors in treating solid tumors.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase I trial examines basroparib in 25 patients with advanced-stage solid tumors, suggesting its potential as a tankyrase inhibitor.

Abstract

Patient demographic and baseline characteristics (N = 25).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lieu et al. (2025) studied this question.

synapsesocial.com/papers/68e5c1ba6950a706b22b5382 https://doi.org/10.1158/2767-9764.30284998

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table 4 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
2Table 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
3Figure 2 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
4Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025
5Data from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors2025

More related papers

TABLE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors2024
Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer2025
Table 1 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer2025